The agreement allows Pfizer to exercise options to license novel capsids generated from Voyager's RNA-driven screener technology, which would be used by Pfizer to develop, make and commercialize gene therapies.
- As part of the agreement, Voyager will receive an upfront payment of $30 million, and is entitled to receive up to $20 million in exercise fees.
- Voyager will also be eligible to receive up to $580 million in milestone payments, and will be eligible to receive "mid- to high-single-digit tiered royalties" based on sales of Pfizer products using the licensed capsids.
No comments:
Post a Comment